Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU

Central Bank Policy

2 articles

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

The European Central Bank meets March 19 amid conflicting signals: February job losses hit 92,000 while oil prices jumped 36% on Iran conflict. Former Fed official Loretta Mester says central banks need 'convincing evidence' of inflation retreat before cutting rates, even as labor markets weaken.

ViaNews Editorial Team (Europe)•
Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Chicago Fed President Alan Goolsbee said interest rates can drop further in 2026 if inflation moderates, contrasting with the ECB's cautious stance. The divergence pressures the euro as US markets rally on dovish Fed signals while European policymakers maintain tighter conditions. Contactless payments in Finland jumped 23% to €8.4 billion in Q2 2025 as payment infrastructure evolves.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com